Development and validation of an immune prognostic signature for ovarian carcinoma
Development and validation of an immune prognostic signature for ovarian carcinoma
复制标题
DOI：
10.1002/cnr2.1166
复制
发表时间：
2020-08-01
期刊：
影响因子：
1.7
通讯作者：
Shukla, Sudhanshu Kumar
中科院分区：
文献类型：
--
作者：
Khadirnaikar, Seema;Kumar, Pranjal;Shukla, Sudhanshu Kumar
背景卵巢癌（OC）在女性癌症相关死亡中占很大比例。最近，免疫疗法已成为癌症治疗的重要参与者。淋巴细胞浸润是免疫活性和疾病侵袭性的重要指标，可以通过肿瘤免疫相关基因的基因表达谱来鉴定，这可能证明对患者的预后有用。本研究的目的是鉴定和验证一种新的基于免疫基因的OC预后标记。方法和结果在此，我们提取了免疫相关基因的表达，并进行了考克斯回归分析，并确定了5个基因与患者的训练队列（n = 286）中的生存显着相关。我们利用回归系数和五个基因的表达水平来计算OC患者的免疫预后特征（IPS）评分。在单因素和多因素考克斯回归分析中，我们发现IPS是生存的独立预测因子（P值
Background Ovarian cancer (OC) causes a significant proportion of cancer-related deaths in women. Recently, immunotherapy has emerged as a substantial player in cancer treatment. Lymphocyte infiltration, an important indicator of immune activity and disease aggressiveness, can be identified by gene expression profiling of immune-related genes of tumours which may prove useful in prognosis of patients. Aims The aim of this study is to identify and validate a novel immune gene-based prognostic signature for OC. Methods and results Here, we extracted the expression of immune-related genes and performed the Cox regression analysis and identified five genes with significant correlation with survival in training cohort of patients (n = 286). We utilised regression coefficient and expression level of five genes to calculate immune prognostic signature (IPS) score for OC patients. In univariate and multivariate Cox regression analysis with other clinicopathological factors, we showed that IPS is an independent predictor of survival (Pvalue